In fact, a clinical trial is currently in progress using the TUSC2 expression plasmid containing DOTAP:cholesterol nanoparticles (REQORSA) in combination with EGFR inhibitor Osimertinib (NCT04486833) in advanced lung cancer patients who experienced disease progression on Osimertinib alone [107]. The gene discussed is EGFR; the disease is lung carcinoma.